Preparation and biodistribution of technetium-99m-labeled 1-(2-nitroimidazole-1-yl)-propanhydroxyiminoamide (N2IPA) as a tumor hypoxia marker

Nuclear Medicine and Biology

Volumn 31, Issue 2, 2004, Pages 199-203

  Chu, Taiwei ^a   Li, Rujun ^a   Hu, Shaowen ^a   Liu, Xinqi ^a   Wang, Xiangyun ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Biodistribution; Hydroxyiminoamide; Hypoxia imaging agent; Tumor

Indexed keywords

1 (2 NITROIMIDAZOL 1 YL)PROPANHYDROXYIMINOAMIDE TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; HEART; HYPOXIA; LIVER; LUNG; MALE; MOUSE; MUSCLE; NONHUMAN; TUMOR;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; IMIDAZOLES; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; MICE; ORGAN SPECIFICITY; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; SARCOMA; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

EID: 1542315602     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2003.08.007     Document Type: Article

References (15)

1. Ballinger J.R., Kee J.W.M., Rauth A.M. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med. 37:1996;1023-1031.
2. m-AIPO. J Nucl Radiochem. 23:2001;145-152.
3. Cook G.J.R., Fogelman I. Tumor hypoxia the role of nuclear medicine. Eur J Nucl Med. 25:1998;335-337.
4. Eloy F., Lenares R. The chemistry of amidoximes and related compounds. Chem Rev. 62:1962;155-183.
5. Grunbaum Z., Freauff S.J., Krohn K.A., et al. Synthesis and characterization of congeners of misonidazole for imaging hypoxia. J Nucl Med. 28:1987;68-75.
6. Hauser C.R., Renfrow W.B. Benzohydroxamic acid. Blatt A.H. Org Syntheses, Coll. Vol. 2. 1943;67-68 John Wiley & Sons, Inc, New York.
7. Mannan R.H., Somayaji V.V., Lee J., et al. Radioiodinated 1-(5-iodo-5-deoxy-á-darabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside:IAZA) a novel marker of tissue hypoxia. J Nucl Med. 32:1991;1764-1770.
8. 99mTc radiopharmaceuticals(I). Nucl Med Commun. 13:1992;445-449.
9. 99mTc complexes of hydroxamamide derivatives. Appl Radiat Isot. 45:1994;735-740.
10. 99mTc radiopharmaceuticals-III. Characterization of various Tc-99m-hydroxamamides. Appl Radiat Isot. 48:1997;571-577.
11. Nunn A., Linder K., Strauss H.W. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med. 22:1995;265-280.
12. Rahman M.F., Neelakantan P., Thyagarajan G. Michael addition of imidazoles with acrylonitrile and acrylic acid. Indian J Chem. 13:1975;531-532.
13. Ramalingam K., Raju N., Nanjappan P., et al. Synthesis of nitroimidazole substituted 3,3,9,9-tetramethyl-4,8-diazaundecane-2,10-dione dioximes (propylene amine oximes, PnAOs) ligands for technetium-99m complexes with potential for imaging hypoxic tissue. Tetrahedron. 51:1995;2875-2894.
14. Sehgal R.K., Agrawal K.C. Hydroxymethlation and cyanoethylation of nitroimidazoles(1). J Heterocyclic Chem. 16:1979;871-876.
15. Yang D.J., Wailace S., Cherif A., et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology. 194:1995;795-800.